Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Baylor Genetics | RCV003472532 | SCV004200358 | uncertain significance | Breast-ovarian cancer, familial, susceptibility to, 4 | 2023-09-17 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004943061 | SCV005485319 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-08-08 | criteria provided, single submitter | clinical testing | The p.Y134H variant (also known as c.400T>C), located in coding exon 5 of the RAD51D gene, results from a T to C substitution at nucleotide position 400. The tyrosine at codon 134 is replaced by histidine, an amino acid with similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the available evidence, the clinical significance of this variant remains unclear. |